CareDx Shares Jump on $170 Million Lab Products Divestment

Apr 15, 2026 20:58 UTC

CDNA

Short term

CareDx has announced the sale of its Lab Products business to EuroBio Scientific for $170 million in cash. The move, coupled with a Q1 pre-announcement, triggered an 8% surge in after-hours trading.

Sale of Lab Products business to EuroBio Scientific
Cash consideration of $170 million
Positive Q1 pre-announcement
Shares rose over 8% in extended trading

CareDx (CDNA) saw its stock price climb more than 8% in extended trading Wednesday following the announcement of a strategic divestiture and positive preliminary financial updates. The Brisbane, California-based precision medicine firm is selling its Lab Products division to EuroBio Scientific. This transaction is part of a broader effort to streamline operations and focus on core diagnostic capabilities. The deal is structured as a cash transaction, with EuroBio Scientific paying $170 million for the business unit. This influx of liquidity comes alongside a Q1 pre-announcement that has further bolstered investor confidence. The market reaction suggests that investors view the divestment as a positive step toward improving the company's balance sheet and operational efficiency. The immediate price action reflects optimism regarding the company's refined strategic direction.